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We describe a 4-generation family in which  
a previously healthy 10-year-old boy died 
of late-onset ornithine transcarbamylase 
(OTC) deficiency. Pedigree analysis and al- 
lopurinol loading tests in female relatives 
were not informative. A m issense mutation 
(A208T) in the OTC gene was detected in the 
deceased patient and in several clinically 
healthy male and fem ale relatives, the old­
est male being 97 years old. OTC deficiency 
was established in  autopsy liver tissue of 
the propositus and liver biopsy samples of 
his sister, mother, and a maternal uncle* The 
m ales had 4%  and 6% residual activity, re­
spectively, the fem ales 58% and 67%, respec­
tively. The observed relation between the 
mutation and the decreased OTC activity in 
liver tissue of these subjects suggests that 
the mutation is a deleterious one. Late-on­
set, “mild” OTC deficiency can have a fatal 
or a favorable outcom e. The disease can seg­
regate undetected in  fam ilies. Am. J. Med. 
Genet. 68:236—239, 1997 © 1997 Wiley-Liss, Inc.
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INTRODUCTION
Ornithine transcarbamylase (OTC) deficiency 
(McKusick #311250) is an X-linked recessive urea cycle 
disorder with variable clinical presentation in hemizy- 
gous males and heterozygous females [Tuchman, 1992]. 
The neonatal phenotype, often leading to early death, 
is caused by complete absence of hepatic OTC activity, 
It is accompanied by severe hyperammonemia, hypo- 
citrullinemia, and orotic aciduria. Males with a partial 
(up to 30% of normal) enzyme deficiency generally are 
free of symptoms but may be at risk during catabolic 
circumstances and/or high protein intake [Finkelstein 
et al., 1990]. Onset in these patients has been reported 
a t any age, the highest two being 46 and 58 years [Mat- 
suda et al., 1991], with symptoms characterized by pro­
tein avoidance, behavior changes, recurrent vomiting, 
lethargy, and coma [Drogari and Leonard, 1988]. Fe­
males heterozygous for OTC deficiency may be asymp­
tomatic or have similarly variable clinical symptoms 
which are explained by random X-chromosome inacti­
vation [Batshaw et al., 1986],
To date, approximately 70 mutations and polymor­
phisms in the OTC gene have been identified [Tuchman 
et al., 1995b]. Except for very few recurrent mutations 
such as the R141Q and R277W mutation, most patients 
with OTC deficiency have unique alterations. Thus far, 
there is no clear genotype-phenotype correlation 
[Oppliger et al., 1995].
In this paper we present the results of clinical, bio­
chemical, and molecular genetic investigations per­
formed in a 4-generation family in which a previously 
healthy boy died of late-onset OTC deficiency at the age 
of 10 years. It is remarkable th a t his great-grandfather, 
who has transm itted the disease, remained asympto­
matic until the age of 97 years.
1997 Wiley-Liss, Inc,
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The propositus (IV-5, Pig. 1), a 10-year-old boy, was 
admitted because of a progressive hepato-encephalopa- 
thy in the course of a protracted viral gastroenteritis. 
Besides unexplained extreme irritability during minor 
illnesses with fever, noticed from the age of 6 years on, 
his medical history was uneventful. Physical examina­
tion on admission showed a severely ill child with peri­
odical restlessness, dry mucosa, a flushed face, wide 
pupils with a positive light reflex, alternating periods of 
bradycardia and tachycardia, slightly diminished deep 
tendon reflexes, and bilateral Babinski reflexes.
The initial blood ammonium level was 529 //mol/L 
{n < 60). Laboratory studies showed the following ab­
normal results: glutamine 2,404 /¿mol/L (n:596 ±  66), 
citrulline 14 //mol/L (n:35 ± 8), arginine 47 //mol/L 
(n:89 ± 20), ornithine 31 /¿mol/L (n:49 ± 14). Urine 
orotic acid was 760 mmol/mol creatinine (n: < 2 .5 ) and 
orotidine was 2.2 mmol/mol creatinine (n: < 2 .5),
Following the recognition of hyperammonemia, pro­
tein intake was stopped immediately and a high- 
caloric carbohydrate infusion was started. Sodium 
benzoate (250 mg/kg body weight) was supplemented 
intravenously during the first two hours followed by 
250 mg/kg bodyweight/24- h  as a continuous infusion. 
This was supported by arginine-HCl, lactulose, folic 
acid and L-carnitine. Despite this treatm ent, the  pa­
tient's clinical condition worsened over the next 
hours, progressing to coma and convulsions. The blood 
ammonium level was still markedly elevated (530 
//,mol/L). Anti-convulsive drug administration, artifi­
cial ventilation and peritoneal dialysis were initiated. 
Unfortunately, hemodialysis, the most powerful tool 
for ammonia removal, could not be performed. Plasma
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Fig. 1. Pedigree of a four-generation family with OTC deficiency 
cuuHcd by a A208T mutation. 0 ,  Female heterozygous for the A20HT 
mutation; ■, male henmygouH for the A208T mutation.
ammonia levels norm alised only after 36 hours of 
treatm ent, however, w ithout any change in the pa­
tient’s critical condition. Repeated EEG recordings 
showed an isoelectric pa tte rn . All trea tm en t was dis­
continued on the  6th day after admission. One hour af­
ter death, autopsy was performed. C erebral edema, 
mild patchy bronchopneumonia and diffuse fatty  
changes of the liver were the  main abnorm alities.
The diagnosis of OTC deficiency was suspected. This 
was supported by low plasm a citrulline and increased 
urinary orotic acid. However, the pedigree (Fig. 1) was 
not informative for a fatal disorder with X~1 inked re- 
ceSvsive inheritance. In order to identify relatives at 
risk, biochemical investigations and DNA analyses 
were performed.
MATERIALS AND METHODS
Autopsy liver tissue of the propositus was stored at 
-70°C until use for enzyme studies, OTC activity was 
determined according to Kleijer et aL [1984] and ex­
pressed as a percentage of the control levels which 
ranged from 192 to 333 nmol/min/mg protein. The al- 
lopurinol loading test was performed as described by 
Hauser et al, [1990]. The orotic acid and orotidine peak 
levels represent the m ean H- 3 S.D., i.e., the  maximum 
value th a t can be observed in controls [Hauser e t al., 
1990]. Plasma ammonium and amino acids were ana­
lyzed with an amino acid analyzer according to the 
m anufacturer’s instructions. Orotic acid and orotidine 
were measured by high performance liquid chromatog­
raphy using diode-array UV-detection. Genomic DNA 
was isolated from peripheral blood leukocytes, and m u­
tation analysis was performed by single-strand confor­
mational polymorphism (SSCP) and direct sequencing 
[Tsai e t al., 1993].
RESULTS
OTC activity in autopsy liver tissue of the propositus 
was 9 nmol/min/mg protein (4% of OTC activity in 
controls), confirming the suspected deficiency of this 
enzyme. SSCP analysis of the exons of the OTC gene 
showed a band shift of the polymerase chain reaction 
(PGR) product of exon 6 . Direct sequencing of the ab­
normal DNA fragm ent identified a A208T m utation in 
the propositus (data not shown). This m utation causes 
a substitution of alanine for threonine. Sequencing of 
all exons, including intron-exon junctions, showed no 
other* m utation. The A208T mutation was detected in 
the propositus* mother and sister, and in several other 
relatives (Fig. 1). Four clinically healthy males (ages 
ranging from 2 to 97 years) were carriers of the mu­
tation.
The allopurinol loading test was performed in the fol­
lowing persons (Fig. 1 ): the mother (ILI-3), sister (IV-6), 
m aternal uncle (III-l) of the propositus as well as in II- 
1 , III-2 , III-4, IV-3 and IV-9. All 3 males who were
tested had abnorm al te s t results, although the varia­
tion in the peak levels of orotic acid and orotidine was 
quite large (Table I). In one female (III-2), urinary 
orotic acid and orotidine excretion were increased. In 
three of 4 abnormal allopurinol loading tests, the uri­
nary orotic acid was markedly higher than  orotidine,
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TABLE I. Results of the Allopurinol Loading Test, Plasma Glutamine and Liver OTC Activity
in Carriers of the A208T Mutation
Allopurinol 
loading test
Person Gender Age (yr)
Orotic acid Orotidine 
peak level peak level
(mmol/mol creatinine)
Liver OTC activity 
(nmol/min/mg protein)
Plasma 
glutamine (/¿mol/L)
1-1 m 97 npa np np
II-1 f 66 3.7 4.4 n p np
III-l m 41 110 18.0 16 706
III-2 f 40 142 1.3.3 np np
III-3 f 35 8.2 3.3 170 611
III-4 f 32 4.1 6.2 np np
IV-3 m 14 1,9.2 1.8 np 7.1.0
IV-5 m 10 np 9 2,404
IV-6 f 3,7 3,8 144 684
IV-9 m 2 8.6 14 np 588 1
Controls 14.4K 9.1c 250 596 ± 66
4).
,Lnp, not performed.
bMean control OTC activity. The control levels ranged from 192 to 333 nmol/min/mg protein (n = 
cThia value represents the mean + 3 S.D., i.e., the maximum value that can be observed in controls [Hauser et al., 19901. 
'’Armstrong and Stae [1973].
The results were norm al in the  other tested individuals 
(Table I). Plasm a glutam ine, ano ther m arker of urea 
cycle disorders, was norm al in all asymptomatic rela­
tives (Table I). In III- l, the  am m onia level increased 
from 44 /¿M to 204 pM  (n:<60) after a protein-rich 
meal. During this episode of hyperammonemia, no neu­
rological or other symptoms were observed. There was 
a persistently low level of p lasm a citrulline. Liver 
biopsy was performed in the m other (III-3), sister (IV-6 ) 
and m aternal uncle (III-l) of the  patient showing 170, 
144 and 16 nmol/min/mg protein OTC activity, respec­
tively (Table I). None of the heterozygous females (II-l, 
II-4, III-2 , III-3, III-4 and IV-6 , Fig. 1 ) ever had expe­
rienced clinical symptoms associated with OTC defi­
ciency.
DISCUSSION
OTC deficiency is anX -linked recessive disorder with 
a variable clinical phenotype. The dramatic clinical 
presentation in male infants is well-known. In patients 
with a partial enzyme deficiency, th e  age of onset may 
vary. The clinical symptoms include bizarre behavior 
[DiMagno et al., 1986; Spada e t al., 1994] and neuro­
logical abnorm alities [Drogari and Leonard, 1988]. 
M atsuda et al. 11991] have shown th a t  late-onset OTC 
deficiency is a potentially lethal disorder. On the other 
hand, our family shows th a t  symptom-free survival up 
to a very advanced age is also possible.
According to Pelet et al. [1990] the prior minimum 
risk of a mother of an  affected male being a carrier is 
84%. Recently, Tuchman et al. [1995a] suggested that 
th is risk is at least 90%. Thus, carrier detection is im­
portan t when OTC deficiency is first diagnosed in a 
family. Carrier detection can be performed by in  vivo 
testing (acute and chronic protein loading tests, allo­
purinol loading test), enzyme analysis in liver biopsy 
samples and molecular genetic investigations. With re­
spect to the allopurinol test, H auser et al. [1990] re­
ported th a t less then  5% of the obligate heterozygotes
did have normal results. However, in the present fam­
ily, the allopurinol test was negative in 4- of the 5 fe­
males tested, indicating tha t this test should not be 
used to identify female carriers in families with late- 
onset OTC deficiency.
In our family, 3 of 4 abnormal allopurinol loading 
tests showed a prevalence of urinary  orotic acid over 
orotidine. This contrasts with the findings of Hauser 
et al. [1990], who suggested th a t orotidine is a better 
marker than orotic acid on allopurinol testing. The in­
dividual activities of pyrimidine nucleoside phosphory- 
lase, catalyzing the conversion of orotidine to orotic 
acid, may influence the ratios of these two substances. 
Plasma glutamine is considered to be a m arker of urea 
cycle disorders, as it is formed from glutam ate and ex­
cess ammonia. In the present family, all tested asymp­
tomatic subjects had normal glutamine levels. From 
th a t we conclude th a t this analyte has no discrimina­
tive power in our family.
In families where the mutation is known, SSCP 
analysis of the OTC gene or direct sequencing are the 
methods of choice for carrier detection [Tsai et al., 
1993], We detected a A208T missense muta Lion in the 
propositus. Sequencing of all exons, including intron- 
exon junctions, showed no other mutation. The A208T 
mutation was present in several other relatives {Fig. 1 ). 
In 3 of them, liver OTC activity was measured (Table I). 
The observed decreased OTC activity in two females 
and the low OTC activity in the propositus and his ma­
ternal uncle seems to confirm the deleterious nature of 
the mutation. The alanine at position 208 is evolution­
ary conserved among mammalian OTC sequences and 
in more than 20 species [Tuchman et al., 1995b], It is 
therefore highly suggestive th a t the alteration is not 
neutral. However, future expression studies of m utant 
cDNA are required to establish firmly the relationship 
between the mutation and the enzyme deficiency.
The OTC activity was not measured in the great­
grandfather of the propositus. He was clinically
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healthy at age 97 years. In the propositus and his uncle 
the OTC activity was 4% and 6%, respectively. The 
propositus died, while his uncle never has had major 
health problems. Apparently, factors other than  in vitro 
OTC activity play a role in the severity of symptoms, 
but this is not well understood [Finkelstein et al., 
1990].
To date, about 70 different mutations (including poly­
morphisms) have been identified in the OTC gene of 
patients with OTC deficiency [Tuchman et al., 1995b]. 
Most individuals with deficient enzyme activity have 
unique mutations, The A208T mutation was described 
previously in a large Polish pedigree with late-onset 
OTC deficiency IBakker et a l ,  1995]. The mutation 
originated from the great-grandfather of the propositus 
who died at the age of 69 years without evidence of 
episodes of hyperammonemia.
In conclusion, we th ink th a t OTC deficiency can seg­
regate undetected in families. When first diagnosed in 
a family, carrier detection is an important aspect of ge­
netic counselling. No relative can be reassured until 
molecular genetic and biochemical investigations have 
been performed. In the reported 4-generation family, 
late-onset OTC deficiency was caused by a missense 
(A208T) mutation. The disease can have a favorable as 
well as a fatal outcome. Consequently, it is important to 
identify individuals at risk.
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